Search

Julie D Seroogy

from San Carlos, CA
Age ~52
Get Report
Also known as:
Julie Seroogy, Julie Dianne Seroogy, Julie Dianne Pryde, Julie Pryde, Juile Pryde
811 Orange Ave, San Carlos, CA 94070
Related to:
Larry B Pryde, 80Lorna J Fontana, 58Joseph J Seroogy, 58Paul G Seroogy, 57Catherine A Ritchay, 50Jean M Seroogy, 82Joseph J Seroogy, 84Vicki Jean Pryde, 78
Connected to:
Nancy C Seroogy, 75Alexander Seropian, 56Carmen P Seropian, 62Diran V Seropian, 61Albert L Seror, 37Jerome Serot, 50Ann P Serota, 66Harvey S Serota, 78Jason M Serota, 49Jodi A Serota, 66

Julie Seroogy Phones & Addresses

  • 811 Orange Ave, San Carlos, CA 94070
  • San Mateo, CA
  • 1242 128Th Ave, Minneapolis, MN 55448
  • 10957 Bluebird St, Minneapolis, MN 55433
  • Coon Rapids, MN
  • San Francisco, CA

Work

Company: Achaogen Jul 2012 Position: Bioanalytical/dmpk consultant

Education

Degree: BS School / High School: Arizona State University 1988 to 1992 Specialities: Zoology

Skills

Assay Development • Glp • Drug Discovery • Biotechnology • Pharmacology • Cro • In Vitro • Drug Development • Life Sciences • Hplc • Dmpk • Pharmaceutical Industry • Pharmacokinetics • In Vivo • Toxicology • Validation • Bioanalysis • Ind • High Performance Liquid Chromatography • Biomarker Discovery • Clinical Development • Clinical Research • Biopharmaceuticals • Lifesciences

Industries

Biotechnology

Resumes

Resumes

Julie Seroogy Photo 1

Senior Director, Clinical Pharmacokinetics

View page
Location:
811 Orange Ave, San Carlos, CA 94070
Industry:
Biotechnology
Work:
Achaogen since Jul 2012
Bioanalytical/DMPK consultant
PharmacoFore, Inc. Jun 2006 - Jun 2012
Director, Research
Theravance 1998 - 2006
Scientist
COR Therapeutics 1995 - 1998
Research Associate
Education:
Arizona State University 1988 - 1992
BS, Zoology
Skills:
Assay Development
Glp
Drug Discovery
Biotechnology
Pharmacology
Cro
In Vitro
Drug Development
Life Sciences
Hplc
Dmpk
Pharmaceutical Industry
Pharmacokinetics
In Vivo
Toxicology
Validation
Bioanalysis
Ind
High Performance Liquid Chromatography
Biomarker Discovery
Clinical Development
Clinical Research
Biopharmaceuticals
Lifesciences

Publications

Us Patents

Pharmaceutical Compositions With Attenuated Release Of Phenolic Opioids

View page
US Patent:
20110281886, Nov 17, 2011
Filed:
Oct 16, 2009
Appl. No.:
13/121335
Inventors:
Thomas E. Jenkins - Half Moon Bay CA, US
Julie D. Seroogy - San Carlos CA, US
Jonathan W. Wray - San Carlos CA, US
International Classification:
A61K 31/485
A61K 31/496
A61P 29/00
A61K 31/495
US Classification:
51425302, 514282, 51425501
Abstract:
Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise a phenolic opioid prodrug that provides enzymatically-controlled release of a phenolic opioid, and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the phenolic opioid from the prodrug so as to attenuate enzymatic cleavage of the prodrug.

Compositions Comprising Enzyme-Cleavable Ketone-Modified Opioid Prodrugs And Optional Inhibitors Thereof

View page
US Patent:
20120230916, Sep 13, 2012
Filed:
Apr 21, 2010
Appl. No.:
13/393470
Inventors:
Thomas E. Jenkins - Half Moon Bay CA, US
Craig O. Husfeld - San Mateo CA, US
Julie D. Seroogy - SAn Carlos CA, US
Jonathan W. Wray - San Francisco CA, US
International Classification:
A61K 49/00
C12Q 1/37
A61K 31/495
A61P 25/00
C07D 489/08
A61K 31/485
US Classification:
424 92, 546 44, 514282, 51425501, 435 23
Abstract:
A method of providing a patient with controlled release of ketone-containing opioid using a prodrug capable, upon enzymatic activation and intramolecular cyclization, of releasing the ketone-containing opioid is disclosed. The disclosure also provides such prodrug compounds and pharmaceutical compositions comprising such compounds. Such pharmaceutical compositions can optionally include an enzyme inhibitor that interacts with the enzyme(s) to mediate the enzymatically-controlled release of the ketone-containing opioid from the prodrug so as to modify enzymatic cleavage of the prodrug. Also included are methods to use such compounds and pharmaceutical compositions.

Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs And Inhibitors Thereof

View page
US Patent:
20130059914, Mar 7, 2013
Filed:
Apr 8, 2011
Appl. No.:
13/634524
Inventors:
Thomas E. Jenkins - Half Moon Bay CA, US
Craig O. Husfeld - San Mateo CA, US
Julie D. Seroogy - San Carlos CA, US
Jonathan W. Wray - San Francisco CA, US
Assignee:
SIGNATURE THERAPEUTICS, INC. - San Carlos CA
International Classification:
A61K 31/197
C07C 279/14
C12Q 1/02
C07C 237/22
A61K 31/165
US Classification:
514563, 564196, 514626, 435 29, 562440
Abstract:
Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise an amphetamine prodrug that provides enzymatically-controlled release of amphetamine or an amphetamine analog. The composition can further comprise an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of amphetamine or the amphetamine analog from the amphetamine prodrug so as to attenuate enzymatic cleavage of the amphetamine prodrug.

Compositions Comprising Enzyme-Cleavable Hydromorphone Prodrug

View page
US Patent:
20130089504, Apr 11, 2013
Filed:
Oct 14, 2010
Appl. No.:
13/634528
Inventors:
Thomas E. Jenkins - Half Moon Bay CA, US
Craig O. Husfeld - San Mateo CA, US
Julie D. Seroogy - San Carlos CA, US
Jonathan W. Wray - San Francisco CA, US
Assignee:
SIGNATURE THERAPEUTICS, INC. - San Carlos CA
International Classification:
A61K 31/439
A61K 31/496
C07D 489/02
US Classification:
424 91, 546 45, 514282, 51425212, 436 93
Abstract:
The embodiments provide Compound PC-5, [2-((S)-2-malonylamino-6-amino-hexanoyl amino)-ethyl]-ethyl-carbamic acid hydromorphone ester, or acceptable salts, solvates, and hydrates thereof. The present disclosure also provides pharmaceutical compositions, and their methods of use, where the pharmaceutical compositions comprise a prodrug, Compound PC-5, that provides enzymatically-controlled release of hydromorphone, and, optionally, a trypsin inhibitor that interacts with the enzyme that mediates the enzymatically-controlled release of hydromorphone from the prodrug so as to attenuate enzymatic cleavage of the prodrug.

Compositions Comprising Enzyme-Cleavable Phenol-Modified Tapentadol Prodrug

View page
US Patent:
20130090379, Apr 11, 2013
Filed:
Oct 14, 2010
Appl. No.:
13/634530
Inventors:
Thomas E. Jenkins - Half Moon Bay CA, US
Julie D. Seroogy - San Carlos CA, US
Jonathan W. Wray - San Francisco CA, US
Assignee:
SIGNATURE THERAPEUTICS, INC. - San Carlos CA
International Classification:
A61K 31/27
C07C 271/52
US Classification:
514482, 560115
Abstract:
A method of providing a patient with controlled release of tapentadol using a prodrug capable, upon enzymatic activation and intramolecular cyclization, of releasing tapentadol is disclosed. The disclosure also provides such prodrug compounds and pharmaceutical compositions comprising such compounds. Such pharmaceutical compositions can optionally include an enzyme inhibitor that interacts with the enzyme(s) to mediate the enzymatically-controlled release of tapentadol from the prodrug so as to modify enzymatic cleavage of the prodrug. Also included are methods to use such compounds and pharmaceutical compositions.

Compositions Comprising Enzyme-Cleavable Phenol-Modified Opioid Prodrugs And Inhibitors Thereof

View page
US Patent:
20130210700, Aug 15, 2013
Filed:
Nov 27, 2012
Appl. No.:
13/686710
Inventors:
Signature Therapeutics, Inc. - , US
Craig O. Husfeld - San Mateo CA, US
Julie D. Seroogy - San Carlos CA, US
Jonathan W. Wray - San Francisco CA, US
Assignee:
Signature Therapeutics, Inc. - San Carlos CA
International Classification:
A61K 47/48
A61K 31/485
US Classification:
514 13, 514282, 546 45, 435 23
Abstract:
Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise a phenol-modified opioid prodrug that provides enzymatically-controlled release of a phenolic opioid, and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the phenolic opioid from the phenol-modified opioid prodrug so as to modify enzymatic cleavage of the phenol-modified opioid prodrug.

Compositions Comprising Enzyme-Cleavable Opioid Prodrugs And Inhibitors Thereof

View page
US Patent:
20130210701, Aug 15, 2013
Filed:
Nov 27, 2012
Appl. No.:
13/686725
Inventors:
Signature Therapeutics, Inc. - , US
Craig O. Husfeld - San Mateo CA, US
Julie D. Seroogy - San Carlos CA, US
Jonathan W. Wray - San Francisco CA, US
Assignee:
SIGNATURE THERAPEUTICS, INC. - San Carlos CA
International Classification:
A61K 47/48
A61K 31/485
US Classification:
514 13, 514282, 546 45, 435 23
Abstract:
Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise an opioid prodrug that provides enzymatically-controlled release of an opioid, and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the opioid from the opioid prodrug so as to attenuate enzymatic cleavage of the opioid prodrug.

Compositions Comprising Enzyme-Cleavable Prodrugs Of Active Agents And Inhibitors Thereof

View page
US Patent:
20130210854, Aug 15, 2013
Filed:
Dec 7, 2012
Appl. No.:
13/708486
Inventors:
Signature Therapeutics, Inc. - , US
Craig O. Husfeld - San Mateo CA, US
Julie D. Seroogy - San Carlos CA, US
Jonathan W. Wray - San Francisco CA, US
Assignee:
SIGNATURE THERAPEUTICS, INC. - San Carlos CA
International Classification:
A61K 9/00
C07D 489/08
US Classification:
514282, 435 23, 546 46
Abstract:
The present disclosure provides pharmaceutical compositions, and their methods of use, where the pharmaceutical compositions comprise a prodrug that provides enzymatically-controlled release of a drug and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the drug from the prodrug so as to attenuate enzymatic cleavage of the prodrug. The disclosure provides pharmaceutical compositions which comprise an enzyme inhibitor and a prodrug that contains an enzyme-cleavable moiety that, when cleaved, facilitates release of the drug.
Control profile
Julie D Seroogy from San Carlos, CA, age ~52 Get Report